hVIVO Secures Major Influenza Drug Trial Contract
Company Announcements

hVIVO Secures Major Influenza Drug Trial Contract

Open Orphan Plc (GB:HVO) has released an update.

hVIVO plc, a leading contract research organisation, has secured its largest field study contract for a Phase 2b trial of an influenza drug candidate, planning to enrol up to 1,000 volunteers. The study will leverage hVIVO’s expanded outpatient facilities and its volunteer recruitment platform, FluCamp, expecting to drive revenue growth and improve resource utilization in FY 2025. CEO Yamin ‘Mo’ Khan highlights the contract as evidence of hVIVO’s effective recruitment and a significant step in the company’s growth strategy.

For further insights into GB:HVO stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskhVIVO Plc to Present at London Healthcare Conference
TipRanks UK Auto-Generated NewsdeskhVIVO Incentivizes Leadership with New LTIP
TipRanks UK Auto-Generated NewsdeskOpen Orphan Plc Triumphs in RSV Antiviral Trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App